📢 Join us at @IP_London We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04) 🔗 www.imperial.ac.uk/jobs/search-... @londonprostate1.bsky.social @connorurol.bsky.social

Description

Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...

imperial.ac.uk

Thank you to @thetimes.com 📰for covering my first major grant success - the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social www.thetimes.com/uk/healthcar...

‘Groundbreaking’ scan for men with prostate cancer could save lives

Researchers hope the technology will help to create personalised treatment plans to prevent the disease becoming terminal

thetimes.com

Great presentation from our PhD fellow Archana 👏🥇 at the RSM London showing the possibilities of immediate bladder pathology at time of TURBT using the Histolog FCM scanner! @archanagk.bsky.social @ip-london.bsky.social #RSMUrology #LaserComplete #TheUrologyFoundation

Working link to full open access article here: www.bmj.com/content/387/...

Chris Hoy and cancer screening: is celebrity campaigning a bad way to make policy?

The response to the Olympian’s call for wider access to prostate cancer screening has been largely uncritical, Margaret McCartney finds Media coverage has been rightly sympathetic to Chris Hoy, one o...

bmj.com

Imperial Prostate@ip-london.bsky.social · 2y ago

In this week's @bmj.com, @mgtmccartney.bsky.social highlights the critical issues with the PSA test for #ProstateCancer screening. The #TRANSFORM trial starts next year and will test new screening pathways. Read the full article here: https://buff.ly/4g1Pmn0

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

It was a record meeting for Imperial Prostate at #BAUSOncology 2024 with presentations on prostate cancer screening, early detection, molecular imaging and discussion of many of our ongoing/upcoming trials from our fellows, lecturers, and consultants #ATLAS #AVIDITY #FLUORESCE #PACIFIC #TRANSFORM